Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients

This article was originally published here

The German company said that 41% of PAH patients transitioning to Adempas therapy after inadequate response to  phosphodiesterase-5 inhibitors (PDE5 inhibitors) achieved the composite primary endpoint, which is

The post Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients appeared first on Pharmaceutical Business review.